Literature DB >> 15982343

FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.

Giovanni F Torelli1, Anna Guarini, Alessandra Porzia, Sabina Chiaretti, Caterina Tatarelli, Daniela Diverio, Roberta Maggio, Antonella Vitale, Jerome Ritz, Robin Foa.   

Abstract

The present study was designed to investigate, in t(4;11)+ adult lymphoid leukaemia (ALL) blast cells, the pathogenetic role of the FLT3 protein, its level of mRNA and protein expression, the degree of constitutive phosphorylation, the possible presence of mutations of the sequence, the capacity of signal transduction and the potential therapeutic role of specific inhibitors. We evaluated nine adult ALL patients carrying this translocation. The increased FLT3 mRNA levels, determined by oligonucleotide microarray analysis, was in agreement with the increased protein expression evaluated by Western blot. The protein was constitutively phosphorylated in all cases analysed. Polymerase chain reaction detected no internal tandem duplication or point mutations. The signal transduction apparatus, after stimulation with the specific ligand, was preserved. We then investigated the effect of specific FLT3 inhibition on signal transduction and survival. The PKC412 inhibitor specifically inhibited ligand-induced phosphorylation; the same inhibitor reduced the survival of leukaemic cells when compared with untreated cells. These data indicate that the FLT3 protein might play a role in this subgroup of ALL with a particularly poor prognosis. Specific inhibition of the kinase receptor must be hypothesised as an innovative therapeutic tool for t(4;11)+ ALL patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982343     DOI: 10.1111/j.1365-2141.2005.05556.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Duplication of Philadelphia chromosome and trisomy of chromosome 21 in a pediatric patient with acute lymphoblastic leukemia.

Authors:  Katerina Katsibardi; Maria Braoudaki; Stefanos I Papadhimitriou; Kalliopi Karamolegou; Fotini Tzortzatou-Stathopoulou
Journal:  Med Oncol       Date:  2010-10-07       Impact factor: 3.064

2.  Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.

Authors:  Malachi Griffith; Obi L Griffith; Kilannin Krysiak; Zachary L Skidmore; Matthew J Christopher; Jeffery M Klco; Avinash Ramu; Tamara L Lamprecht; Alex H Wagner; Katie M Campbell; Robert Lesurf; Jasreet Hundal; Jin Zhang; Nicholas C Spies; Benjamin J Ainscough; David E Larson; Sharon E Heath; Catrina Fronick; Shelly O'Laughlin; Robert S Fulton; Vincent Magrini; Sean McGrath; Scott M Smith; Christopher A Miller; Christopher A Maher; Jacqueline E Payton; Jason R Walker; James M Eldred; Matthew J Walter; Daniel C Link; Timothy A Graubert; Peter Westervelt; Shashikant Kulkarni; John F DiPersio; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Exp Hematol       Date:  2016-05-13       Impact factor: 3.084

3.  The use of microarray technologies in clinical oncology.

Authors:  L Gabriele; F Moretti; M A Pierotti; F M Marincola; R Foà; F M Belardelli
Journal:  J Transl Med       Date:  2006-02-07       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.